Advanced Search


Study ID Status Title Patient Level Data
112018 Completed Phase I study of GW685698X-A randomized, double blind, placebo controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dose from a novel dry powder device in healthy Japanese male subjects. Study Listed on
112021 Completed Long term antibody persistence study of GSK Biologicals’ meningococcal vaccine GSK 134612 administered as 1 or 2 doses to healthy toddlers at 9-12 months of age and as a booster dose at 5 years post-primary vaccination Study Listed on
112022 Completed Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects Study Listed on
112024 Completed Gynaecological follow-up of a subset of 580299/008 study subjects
112025 Completed A multi-centre, randomized, double-blind, five-way crossover study evaluating the dose response and duration of action of GSK2190915 compared to placebo in subjects with mild asthma who experience exercise induced bronchoconstriction. Study Listed on
112034 Completed A Two Part Single Dose, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations, Drug Interaction and Food Effect on an GSK1322322 in Healthy Subjects Study Listed on
112036 Completed Persistence of antibodies after GSK Biologicals’ meningococcal vaccine GSK134612 in toddlers Study Listed on
112046 Terminated The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils Study Listed on
112059 Completed A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents. Study Listed on
112060 Completed A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powder (GW642444) and salmeterol, compared with placebo in the treatment of persistent asthma in adults and adolescents uncontrolled on inhaled corticosteroids Study Listed on
112065 Completed Safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV/Hib) in infants
112071 Completed An open-label, randomised, single-dose, multi-cohort, crossover bioavailability study of a solution formulation and three capsule formulations of GSK2190915 in healthy adult subjects followed by a repeat-dose, randomized, parallel group, double-blinded study of one selected capsule formulation and matched placebo in elderly healthy subjects Study Listed on
112076 Completed A study to evaluate GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in healthy young adults
112077 Completed Immunogenicity and safety study of different formulations of GSK Biologicals’ herpes zoster vaccine 1437173A when administered twice in adults aged 50 years and older
112110 Completed An Open-Label, Dose-Escalation, Phase IB II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Everolimus in Subjects with Solid Tumors
112111 Completed A Phase IB Combination Study of MEK inhibitor GSK1120212 with Gemcitabine in Subjects with Solid Tumors
112115 Completed Comparison of the immunogenicity and safety of various investigational and licensed formulations of Hepatitis B surface antigen (HBsAg) vaccines.
112121 Recruiting A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine
112132 Withdrawn A Phase II Study to Evaluate Foretinib in Genomic Subpopulations of Subjects with Non-Small-Cell Lung Cancer (NSCLC)
112135 Completed Identification and characterization of the bacteria causing Acute Otitis Media (AOM) episodes in Human deficiency virus (HIV)-positive and HIV-negative children in South Africa
112145 Withdrawn A randomized, double-blind, placebo-controlled, parallel group study to investigate the ability of GSK706769 to maintain clinical remission after withdrawal of Enbrel in patients with rheumatoid arthritis
112146 Completed A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy Japanese subjects Study Listed on
112147 Completed Observer-blind immunogenicity study of GSK Biologicals’ influenza vaccine GSK2186877A in elderly subjects Study Listed on
112148 Completed Persistence of antibodies after vaccination with GSK Biologicals’ meningococcal vaccine GSK134612 in adolescents and young adults
112157 Completed Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 3 and 4 months of age Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.